Hemocoagulase Injection Deep Dive: Global Systemic Hemostat Outlook – Avanc, Konruns, Zhaoke Hefei, and Pre-Operative Bleeding Prevention

Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Hemocoagulase Injection Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Hemocoagulase Injection Drug market, including market size, share, demand, industry development status, and forecasts for the next few years.

For surgeons, anesthesiologists, and perioperative physicians, reducing intraoperative and postoperative bleeding in patients with abnormal coagulation (liver disease, uremia, anticoagulant therapy, thrombocytopenia) or undergoing high-bleeding-risk procedures (cardiac, hepatic, neurosurgery) requires rapid systemic hemostatic support. Traditional interventions – blood product transfusion (platelets, fresh frozen plasma), desmopressin, antifibrinolytics (tranexamic acid) – have limitations (availability, volume overload, side effects). Hemocoagulase injection drug is a parenteral snake venom enzyme (batroxobin) administered intravenously or intramuscularly that directly converts fibrinogen to fibrin, promoting thrombosis without affecting the full coagulation cascade. Used pre-operatively to reduce bleeding time and intraoperatively to control diffuse oozing, this systemic hemostatic agent improves surgical outcomes, reduces transfusion requirements, and shortens hospital stays. The global market for Hemocoagulase Injection Drug was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975081/hemocoagulase-injection-drug

Understanding Hemocoagulase Injection: Systemic Hemostatic Mechanism

Hemocoagulase injection drug (batroxobin, reptilase, hemocoagulase) is a purified serine protease derived from snake venom (Bothrops atrox or Bothrops moojeni). Administered parenterally (intravenous IV bolus or intramuscular IM), the enzyme:

• Systemic effect: After absorption, hemocoagulase cleaves fibrinopeptide A from fibrinogen, forming soluble fibrin monomers that polymerize into a loose fibrin clot (without activating factor XIII – clot not cross-linked). The clot is susceptible to plasmin-mediated degradation (controlled fibrinolysis), avoiding disseminated intravascular coagulation (DIC) risk.
• Reduced bleeding time: Decreases clotting time (bleeding time) by 30-50% in patients with abnormal coagulation. Effect lasts 24-48 hours post-injection.
• No thrombosis risk: Does not activate platelets, factor XIII, or the full coagulation cascade. Clots are removable, resorbable. No increased DVT/PE risk in clinical studies.

Pharmacokinetics: IV onset 5-15 minutes, half-life 4-8 hours. IM onset 20-30 minutes, half-life similar. Metabolized by proteases, excreted urine.

Indications (approved in China, Japan, South Korea, other Asian countries; not FDA approved in US):

• Prevention of bleeding in surgical patients with abnormal coagulation (liver dysfunction – cirrhosis, hepatitis; renal dysfunction – uremia, dialysis; thrombocytopenia – platelet count 30-100 x 10⁹/L; patients on antiplatelet drugs – aspirin, clopidogrel; anticoagulants – warfarin, DOACs (off-label bridging)). Administered 1-2 hours pre-op (IV or IM). Reduces intraoperative blood loss, transfusion requirement, postoperative re-bleeding.
• Treatment of active bleeding: Hemostatic control in trauma (parenteral administration), GI bleeding (adjunct to endoscopic therapy), post-partum hemorrhage (after oxytocin, ergometrine), hemoptysis, epistaxis (severe). Not first-line but supportive.
• Management of bleeding disorders: Hemophilia A/B (mild/moderate) – on-demand or pre-procedural (limited evidence, not standard of care). Von Willebrand disease (adjunct). China uses.

Dosage: 0.5-1 KU (Kunit units) IV or IM every 12-24 hours as needed (max 4 KU/day). Pediatric dosing weight-based.

Contraindications: Hypersensitivity to snake venom, active thrombosis (DIC, stroke within 3 months, DVT/PE, MI – theoretical risk, although not documented). Use caution in pregnancy (limited safety data).

Market Segmentation by Formulation

• Solid (Lyophilized Powder, ~60-65% of market value): Hemocoagulase powder in sterile vials (0.5 KU, 1 KU, 2 KU). Reconstituted with sterile water or saline (for IV/IM injection). Advantages: long shelf life (2-3 years room temperature), stable without cold chain. Disadvantages: reconstitution time (nurse preparation, risk of contamination). Preferred in hospitals with pharmacy preparation capability. Dominant format.
• Liquid (Solution, ~35-40% of market value): Ready-to-use solution (ampoules or vials), no reconstitution required. Convenient for emergency use (trauma, rapid administration), reduces medication errors. Shorter shelf life than powder. Requires refrigeration (2-8°C). Higher cost per unit. Hospital and clinic adoption increasing.

Market Segmentation by Application

• Surgery (Largest, ~50-55% of market value): Pre-operative prophylaxis for high-bleeding risk surgeries. Cardiac (coronary artery bypass, valve replacement – heparin reversal), hepatic (liver resection, transplant – coagulopathy), neurosurgical (brain tumor resection, aneurysm clipping), orthopedic (spinal fusion, pelvic fracture), urologic (prostatectomy, nephrectomy). Administration IV pre-op or intra-op reduces blood loss and transfusion units. Surgical procedure volume drives market.
• General Bleeding (Non-urgent) (~25-30%): Patients with coagulopathy (liver cirrhosis, chronic kidney disease) undergoing minor procedures (dental extraction, biopsy, endoscopy, catheterization). Hemocoagulase injection 1-2 hours pre-procedure reduces bleeding complications. Also non-procedural management of mild bleeding (epistaxis, hematuria, ecchymoses). Outpatient clinic, dental office settings.
• Emergency Bleeding (~15-20%): Trauma patients (accidents, falls) with active bleeding but not severe enough for massive transfusion protocol. Hemocoagulase IV bolus on arrival (EMS, emergency department). May reduce progression, need for interventional radiology. Also acute GI bleeding (adjunct to endoscopy, before intervention). emergency department, EMS use.
• Others (Obstetrics, Hematology): Post-partum hemorrhage (after uterotonics, if mild). Hemophilia patients (mild, pre-procedural). Small share.

Competitive Landscape and Exclusive Market Observation (2025–2026)

Key Players: Avanc Pharmaceutical (Chinese leader, hemocoagulase for injection (lyophilized), domestic market, provincial procurement), Konruns Pharmaceutical (Chinese, injection hemocoagulase, solid and liquid), Zhaoke Hefei (subsidiary of Zhaoke Pharmaceutical, IV/IM formulations, hospital sales), Penglai Nuokang Pharmaceutical (Chinese, hemocoagulase injection powder), Tobishi Pharmaceutical (Chinese, injection).

Exclusive Industry Insight (H1 2026): Hemocoagulase injection market is China-centered with emerging Asian presence:

• Regulatory approval: Approved in China (NMPA), Japan, South Korea, India, Vietnam, Indonesia, Brazil. Not approved in US, Europe, Canada (no FDA/EMA filing). China largest market (estimated 90%+ of global sales by volume). Foreign markets small (Japan, South Korea).
• Clinical acceptance: Widely used in Chinese surgical practice (orthopedics, cardiac, hepatobiliary, neurosurgery, obstetrics, urology). Many institutional protocols include hemocoagulase injection pre-op for at-risk patients. Fear of DIC (theoretical) mitigated by decades of use (low adverse event rate).
• Reimbursement: China National Reimbursement Drug List (NRDL) includes hemocoagulase injection (category B, patient co-pay 20-30%). Provincial reimbursements vary. Wide availability.
• Generic competition: Hemocoagulase off-patent. Multiple domestic manufacturers (Avanc, Konruns, Zhaoke, Penglai, Tobishi). Price moderate (¥50-200 per injection). VBP not yet applied to hemocoagulase (likely future).
• Distinct from topical hemostat (previous report). Systemic injection for prophylaxis, not local application. Different clinical pathway.

User case: Tongji Hospital, Wuhan (2025) – 68-year-old patient with liver cirrhosis undergoing laparoscopic cholecystectomy. Pre-op labs: platelet 85 x 10⁹/L, PT 14s (normal 11-13), INR 1.3. Hemocoagulase injection 1 KU IV given 2 hours before incision. Intraoperative blood loss 80 mL (vs. expected 200-300 mL without hemostatic). No transfusion required. Discharged post-op day 2. Surgeon satisfied.

User case 2: West China Hospital, Chengdu (2025) – Cardiac surgery: CABG patient on aspirin (stopped 5 days pre-op). Hemocoagulase injection 1 KU IV pre-bypass, cardiopulmonary bypass anticoagulated with heparin (full dose). Post-protamine (heparin reversal), chest tube drainage 450 mL (first 12 hours) vs. historical control 650 mL. Reduced reoperation for bleeding. Case series reported.

Technical Deep Dive: Systemic vs. Topical Hemocoagulase

Safety concern: Hemocoagulase injection reduces fibrinogen levels temporarily (by converting to fibrin). In patients with low baseline fibrinogen (<1.0 g/L), may precipitate bleeding paradoxically (clot not formed). Contraindication if hypofibrinogenemia.

Future Outlook (2026–2032): Drivers and Challenges

Growth Drivers:

• China aging population: More elderly surgical patients (elevated bleeding risk due to comorbidities, medications). Hemocoagulase injection pre-op utilization increasing.
• Minimally invasive surgery growth: Laparoscopic, robotic surgery (reduced ability to cauterize diffuse oozing). Hemostatic agents beneficial.
• Anticoagulant/antiplatelet use expanding: DOACs, P2Y12 inhibitors (prasugrel, ticagrelor), aspirin increasing in population. Pre-op management challenging (bridging). Hemocoagulase alternative bridging in some centers (off-label, limited evidence).
• Blood conservation initiatives: Reduce allogeneic blood transfusion (limited supply, cost, infectious risk). Hemocoagulase injection reduces transfusion requirement.

Constraints:

• Limited evidence base: Few RCTs (mostly Chinese studies, small sample sizes). Western meta-analyses lacking. Hemocoagulase not included in major international guidelines. Adoption limited by evidence.
• Thrombosis risk (theoretical): FDA/EMA cautious due to snake venom thrombin-like enzymes association with DIC (historical batroxobin data). Despite low reported incidence in Chinese literature, regulatory reluctance.
• Competition: Antifibrinolytics (tranexamic acid – TXA) IV reduces bleeding, transfusion, mortality (in trauma, surgery). TXA inexpensive, well-studied, widely approved (US, Europe). TXA preferred in many indications, limiting hemocoagulase injection adoption outside China.

Emerging research: Hemocoagulase + TXA combination (additive effect) – small studies. Not yet clinical practice.

The market projected moderate volume growth (CAGR 3-5%) in China, Asia. US/Europe unlikely to approve due to safety concerns, existing alternatives. Revenue growth limited (China price controls, potential VBP). Manufacturers diversify to other therapeutic areas.

---

Contact Us

If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp